TY - JOUR
T1 - A multicenter randomized controlled trial of two group education programs for fatigue in multiple sclerosis
T2 - Short- and medium-term benefits
AU - On Behalf of the VA MS Fatigue Study Group
AU - Hugos, Cinda L.
AU - Chen, Zunqiu
AU - Chen, Yiyi
AU - Turner, Aaron P.
AU - Haselkorn, Jodie
AU - Chiara, Toni
AU - McCoy, Sean
AU - Bever, Christopher T.
AU - Cameron, Michelle H.
AU - Bourdette, Dennis
N1 - Publisher Copyright:
© The Author(s), 2017.
PY - 2019/2/1
Y1 - 2019/2/1
N2 - Background: Fatigue occurs in 75%–95% of people with multiple sclerosis (MS) and is frequently reported as the most disabling symptom. A multicomponent group program of six weekly 2-hour sessions, Fatigue: Take Control (FTC), was developed from an international MS fatigue management guideline. Objective: To determine whether FTC is associated with greater improvements in fatigue than MS: Take Control (MSTC), a similarly structured general MS education program. Methods: This four-site, parallel, single-blind, randomized controlled trial compared FTC and MSTC in 204 ambulatory participants with MS. The primary outcome, the Modified Fatigue Impact Scale (MFIS), and secondary outcomes of self-efficacy, physical activity, sleep, and medications were assessed at baseline, program completion, and 3 and 6 months later. Results: Mean MFIS scores improved in both groups between baseline and program completion (FTC −4.4, p < 0.001; MSTC −3.8, p < 0.001), between baseline and 3 months after program completion (FTC −3.2, p = 0.01; MSTC −3.3, p = 0.01), and between baseline and 6 months after program completion (FTC −5.2, p < 0.001; MSTC −4.8, p < 0.001). These improvements were not statistically different between groups (p = 0.64, 0.92, and 0.82, respectively). Conclusion: Participation in FTC modestly improved self-reported fatigue for up to 6 months. This improvement did not differ significantly from that occurring with the control program.
AB - Background: Fatigue occurs in 75%–95% of people with multiple sclerosis (MS) and is frequently reported as the most disabling symptom. A multicomponent group program of six weekly 2-hour sessions, Fatigue: Take Control (FTC), was developed from an international MS fatigue management guideline. Objective: To determine whether FTC is associated with greater improvements in fatigue than MS: Take Control (MSTC), a similarly structured general MS education program. Methods: This four-site, parallel, single-blind, randomized controlled trial compared FTC and MSTC in 204 ambulatory participants with MS. The primary outcome, the Modified Fatigue Impact Scale (MFIS), and secondary outcomes of self-efficacy, physical activity, sleep, and medications were assessed at baseline, program completion, and 3 and 6 months later. Results: Mean MFIS scores improved in both groups between baseline and program completion (FTC −4.4, p < 0.001; MSTC −3.8, p < 0.001), between baseline and 3 months after program completion (FTC −3.2, p = 0.01; MSTC −3.3, p = 0.01), and between baseline and 6 months after program completion (FTC −5.2, p < 0.001; MSTC −4.8, p < 0.001). These improvements were not statistically different between groups (p = 0.64, 0.92, and 0.82, respectively). Conclusion: Participation in FTC modestly improved self-reported fatigue for up to 6 months. This improvement did not differ significantly from that occurring with the control program.
KW - Multiple sclerosis
KW - clinical trial
KW - fatigue
KW - rehabilitation
KW - self-care
UR - http://www.scopus.com/inward/record.url?scp=85043367652&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85043367652&partnerID=8YFLogxK
U2 - 10.1177/1352458517745723
DO - 10.1177/1352458517745723
M3 - Article
AN - SCOPUS:85043367652
SN - 1352-4585
VL - 25
SP - 275
EP - 285
JO - Multiple Sclerosis Journal
JF - Multiple Sclerosis Journal
IS - 2
ER -